Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114957 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)
A Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT02114957: Completed Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
NCT02114957 is a Early Phase 1 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02114957, a Early Phase 1 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is to investigate how human bodies absorb and metabolize two herbal drugs. The information is critical for drug development and could not be obtained from any other studies using animals. The two herbal drugs are decursin and decursinol angelate (DA) which naturally exist in a traditional herb Angelica gigas Nakai (AGN). Preclinical and clinical studies indicated that AGN and decursin/DA were quite safe to animals and human.
Interventions
- DIETARY_SUPPLEMENT 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-01 |
| Phase | Early Phase 1 |
What the finished NCT02114957 record still lists
NCT02114957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0 is the first listed.
NCT02114957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02114957 about?
NCT02114957 is a clinical study titled "Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)". This study is to investigate how human bodies absorb and metabolize two herbal drugs. The information is critical for drug development and could not be obtained from any other studies using animals. The two herbal drugs are decursin and decursinol angelate (DA) which naturally exist in a traditional...
What is the current status of trial NCT02114957?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2013-01.
What interventions are being tested in trial NCT02114957?
The interventions under investigation include: 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02114957?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02114957's enrollment target sits among peer trials
20 1157th of 2000 higher than 709 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia